Cullinan Therapeutics (CGEM) Research & Development (2020 - 2026)

Cullinan Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $42.1 million for Q1 2026.

• On a quarterly basis, Research & Development rose 1.6% year-over-year to $42.1 million in Q1 2026; TTM through Mar 2026 was $188.1 million, a 22.35% increase from a year earlier, with the FY2025 full-year figure at $187.4 million, up 31.14% from the prior year.
• Research & Development fell to $42.1 million in Q1 2026 per CGEM's latest filing, from $42.9 million in the prior quarter.
• Across five years, Research & Development topped out at $61.0 million in Q2 2025 and bottomed at $19.7 million in Q3 2022.
• The 5-year median for Research & Development is $35.5 million (2024), against an average of $36.0 million.
• Across the five-year window, Research & Development soared 124.24% in 2022 and slumped 41.17% in 2024, its largest moves.
• Year by year, Research & Development stood at $21.3 million in 2022, then surged by 63.44% to $34.8 million in 2023, then grew by 16.2% to $40.5 million in 2024, then gained by 6.06% to $42.9 million in 2025, then decreased by 1.91% to $42.1 million in 2026.
• Per Business Quant, the three latest CGEM Research & Development figures stand at $42.1 million (Q1 2026), $42.9 million (Q4 2025), and $42.0 million (Q3 2025).